<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02276066</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201400795-N</org_study_id>
    <secondary_id>P50GM111152-01</secondary_id>
    <nct_id>NCT02276066</nct_id>
  </id_info>
  <brief_title>Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS</brief_title>
  <official_title>Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care Subtitle. Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the mechanism by which kidney dysfunction perpetuates inflammation,&#xD;
      immunosuppression, and catabolism (PICS) in chronic critical illness. The investigators will&#xD;
      test the hypothesis that persistent kidney dysfunction in sepsis associated by chronic&#xD;
      critical illness contributes to decreased survival through the development of PICS. In&#xD;
      chronic critical illness, the persistence of the inflammatory state may lead to capillary&#xD;
      rarefication in the kidney causing accelerated chronic kidney disease. Progression of chronic&#xD;
      kidney disease during chronic critical illness can drive PICS. Indeed, many of the features&#xD;
      of chronic critical illness are consistent with the protein-energy malnutrition and muscle&#xD;
      wasting associated with chronic kidney disease. Thus, the kidney can play a contributory role&#xD;
      in chronic critical illness and PICS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main goal of this project is to measure kidney filtration function at day 14 or the day&#xD;
      of discharge from hospital (whichever occurs first), in order to determine the presence and&#xD;
      magnitude of persistent kidney dysfunction after sepsis episode and to longitudinally assess&#xD;
      further decline of kidney function at one year follow-up. The measure of the glomerular&#xD;
      filtration rate (GRF) in patients with chronic critical illness and controls (sepsis patients&#xD;
      discharged from ICU before day 14) will be used to determine to what degree of kidney&#xD;
      dysfunction contributes to decreased survival and increase in chronic kidney disease at year&#xD;
      one after sepsis onset.&#xD;
&#xD;
      One and/or all of the three ways for GFR assessment will be used, both at approximately day&#xD;
      14 or approximately at the day of discharge from the ICU and at the one year follow up :&#xD;
&#xD;
        1. Determine clearance of Iohexol from blood after Iohexol injection and/or&#xD;
&#xD;
        2. Determine apperance of Iohexol in urine after Iohexol injection (this would be the same&#xD;
           injection as in one, and would not require two injections) and/or&#xD;
&#xD;
        3. A timed urine collection to determine clearance of urea and creatinine and/or&#xD;
&#xD;
        4. Estimated GFR using calculations with serum creatinine and cystatin C,&#xD;
&#xD;
      This will provide an opportunity to validate the different measurements.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Actual">November 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve versus time curve (AUC) of Iohexol</measure>
    <time_frame>0, 1, 2, 3, and 4 hours post-dose</time_frame>
    <description>The decline in iohexol glomerular filtration rate at day 14 and 1 year follow-up between chronic crucial illness and control groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>Day 14</time_frame>
    <description>The correlation between iohexol glomerular filtration rate and estimated glomerular filtration rate using previously validated equation applied to serum creatinine in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>1 year</time_frame>
    <description>The correlation between iohexol glomerular filtration rate and estimated glomerular filtration rate using previously validated equation applied to serum creatinine in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Urea Concentration</measure>
    <time_frame>Day 14</time_frame>
    <description>The urine will be collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of urea concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Urea Concentration</measure>
    <time_frame>1 year</time_frame>
    <description>The urine will be collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of urea concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Creatinine Ratio</measure>
    <time_frame>Day 14</time_frame>
    <description>The urine will be collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Creatinine Ratio</measure>
    <time_frame>1 year</time_frame>
    <description>The urine will be collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Inhospital group at day 14</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of sepsis participants will remain hospitalized after day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Released from hosptial prior to day 14</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This group of sepsis participants will be released from the hospital prior to day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Both groups of sepsis participants will receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year.</description>
    <arm_group_label>Inhospital group at day 14</arm_group_label>
    <arm_group_label>Released from hosptial prior to day 14</arm_group_label>
    <other_name>omnipaque</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urine Collection</intervention_name>
    <description>Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration.</description>
    <arm_group_label>Inhospital group at day 14</arm_group_label>
    <arm_group_label>Released from hosptial prior to day 14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine and cystatin C results.</description>
    <arm_group_label>Inhospital group at day 14</arm_group_label>
    <arm_group_label>Released from hosptial prior to day 14</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence in the surgery or trauma ICU&#xD;
&#xD;
          -  Age of â‰¥18 years&#xD;
&#xD;
          -  Entrance into our sepsis protocol&#xD;
&#xD;
          -  Ability to obtain informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Expected lifespan of the patient is less than 3 months due to severe pre-existing&#xD;
             comorbidities (ex. recurrent, advanced or metastatic cancer)&#xD;
&#xD;
          -  Severe traumatic brain injury (evidence of neurologic injury on CT scan and a GCS &lt;8)&#xD;
&#xD;
          -  Refractory shock (i.e., patients who die within 12 hours)&#xD;
&#xD;
          -  Uncontrollable source of sepsis (e.g., irreversible disease state such as unresectable&#xD;
             dead bowel)&#xD;
&#xD;
          -  Patient or patient's family are not committed to aggressive management of the&#xD;
             patient's condition and/or the patient has a DNR/DNI on file.&#xD;
&#xD;
          -  Severe CHF (NY Heart Association Class IV)&#xD;
&#xD;
          -  Child-Pugh C liver disease or pre-liver transplant.&#xD;
&#xD;
          -  Known HIV infection with CD4 count &lt;200 cells/mm3&#xD;
&#xD;
          -  Organ transplant recipient on immunosuppressive agents&#xD;
&#xD;
          -  Known pregnancy and mother's that are breastfeeding&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Institutionalized patients&#xD;
&#xD;
          -  Inability to obtain informed consent.&#xD;
&#xD;
          -  Chemotherapy or radiotherapy within 30 days prior to sepsis.&#xD;
&#xD;
          -  End stage renal disease on admission.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Segal, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UF Health at Shands hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney dysfunction</keyword>
  <keyword>chronic critical illness</keyword>
  <keyword>sepsis</keyword>
  <keyword>Glomerular filtration rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

